- Directors and Auditors
- Articles of Association
- General Meetings
- - Previous General Meetings
- Insider Trading
Dignitana newsletter highlights growth, media coverage and exemplary customer satisfaction
Dignitana AB today publishes the investor newsletter highlighting the Company's initiatives to increase awareness, accessibility, affordability, and happiness. With a customer satisfaction score of 97 percent, Dignitana is delivering on its vision of providing DigniCap scalp cooling to more cancer patients than ever before. To read the December newsletter click here or visit Dignitana.com.
The newsletter features media coverage of DigniCap patients, the Company's partnership with leading cancer charity Susan G. Komen, new locations and other recent notable activities.
To receive future Dignitana news directly to your email, subscribe here.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, email@example.com +1 469-518-5031
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.